FutureChem Obtains Patent Rights for Radiopharmaceuticals to Treat Prostate Cancer in Australia
[Asia Economy Reporter Minji Lee] FutureChem announced on the 14th that it has obtained a patent for a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical for the diagnosis and treatment of prostate cancer in the Australian market.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The company stated, "The compound included in the patent has the characteristic of specifically binding to PSMA and can be applied to the development of diagnostic and therapeutic drugs for prostate cancer."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
